Abstract
Osteolytic lesions with activated osteoclast (OC) and suppressed osteoblast (OB) activity are characteristics of myeloma bone lesion. Recently, it has been shown that bortezomib treatment enhances OB function. To evaluate the effect of bortezomib on myeloma bone lesions, we performed bone scans, where increased uptake of the radiopharmaceutical by OBs is associated with re-building activity. Bortezomib treatment markedly enhanced bone metabolic activity and increased alkaline phosphatase levels, and decreased monoclonal protein levels. These findings suggest that bortezomib has potent anti-myeloma activity and bone-protecting effects, with enhanced OB function.
| Original language | English |
|---|---|
| Pages (from-to) | 83-86 |
| Number of pages | 4 |
| Journal | European Journal of Haematology |
| Volume | 86 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2011 |
Bibliographical note
Funding Information:The authors wish to acknowledge the Portuguese foundation for science and technology ( FCT ) for the PhD scholarship granted to A. Abbass ( SFRH/BD/144106/2019 ).
Keywords
- Bone scan
- Bortezomib
- Multiple myeloma
- Osteoblastic activity
Fingerprint
Dive into the research topics of 'Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver